Literature DB >> 23291100

The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.

Michelle A Lowes1, Chris B Russell, David A Martin, Jennifer E Towne, James G Krueger.   

Abstract

Psoriasis is a complex inflammatory process resulting from activation of the well-defined interleukin (IL)-23/T17 cytokine axis. We review the role of key cytokines IL-17 and IL-23 in psoriasis, as well as tumor necrosis factor (TNF)α, focusing on therapeutic cytokine interventions and what they reveal about psoriatic inflammation. The potential role of recently described epidermal IL-36RN and CARD14 genetic mutations in psoriasis pathogenesis is also explored, because they augment keratinocyte responses to proinflammatory cytokines. The discovery of these genetic mutations in familial and pustular psoriasis suggests new links between cytokine-induced gene products and IL-1 family members from keratinocytes, which may regulate features of the disease, including epidermal hyperplasia and neutrophil infiltrating responses.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23291100      PMCID: PMC3721313          DOI: 10.1016/j.it.2012.11.005

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  98 in total

Review 1.  Orchestrating the orchestrators: chemokines in control of T cell traffic.

Authors:  Shannon K Bromley; Thorsten R Mempel; Andrew D Luster
Journal:  Nat Immunol       Date:  2008-09       Impact factor: 25.606

2.  Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis.

Authors:  Ilona Kryczek; Allen T Bruce; Johann E Gudjonsson; Andrew Johnston; Abhishek Aphale; Linhua Vatan; Wojciech Szeliga; Yin Wang; Yan Liu; Theodore H Welling; James T Elder; Weiping Zou
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets.

Authors:  Julie C Ribot; Ana deBarros; Dick John Pang; Joana F Neves; Victor Peperzak; Scott J Roberts; Michael Girardi; Jannie Borst; Adrian C Hayday; Daniel J Pennington; Bruno Silva-Santos
Journal:  Nat Immunol       Date:  2009-03-08       Impact factor: 25.606

Review 4.  Resident and "inflammatory" dendritic cells in human skin.

Authors:  Lisa C Zaba; James G Krueger; Michelle A Lowes
Journal:  J Invest Dermatol       Date:  2008-08-14       Impact factor: 8.551

5.  Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways.

Authors:  K E Nograles; L C Zaba; E Guttman-Yassky; J Fuentes-Duculan; M Suárez-Fariñas; I Cardinale; A Khatcherian; J Gonzalez; K C Pierson; T R White; C Pensabene; I Coats; I Novitskaya; M A Lowes; J G Krueger
Journal:  Br J Dermatol       Date:  2008-08-05       Impact factor: 9.302

Review 6.  Psoriasis and metabolic disease: epidemiology and pathophysiology.

Authors:  Rahat S Azfar; Joel M Gelfand
Journal:  Curr Opin Rheumatol       Date:  2008-07       Impact factor: 5.006

7.  Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15.

Authors:  Ronald Wolf; O M Zack Howard; Hui-Fang Dong; Christopher Voscopoulos; Karen Boeshans; Jason Winston; Rao Divi; Michele Gunsior; Paul Goldsmith; Bijan Ahvazi; Triantafyllos Chavakis; Joost J Oppenheim; Stuart H Yuspa
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

8.  Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells.

Authors:  Lisa C Zaba; Judilyn Fuentes-Duculan; Narat John Eungdamrong; Maria Veronica Abello; Inna Novitskaya; Katherine C Pierson; Juana Gonzalez; James G Krueger; Michelle A Lowes
Journal:  J Invest Dermatol       Date:  2008-07-17       Impact factor: 8.551

9.  Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.

Authors:  Rajan P Nair; Kristina Callis Duffin; Cynthia Helms; Jun Ding; Philip E Stuart; David Goldgar; Johann E Gudjonsson; Yun Li; Trilokraj Tejasvi; Bing-Jian Feng; Andreas Ruether; Stefan Schreiber; Michael Weichenthal; Dafna Gladman; Proton Rahman; Steven J Schrodi; Sampath Prahalad; Stephen L Guthery; Judith Fischer; Wilson Liao; Pui-Yan Kwok; Alan Menter; G Mark Lathrop; Carol A Wise; Ann B Begovich; John J Voorhees; James T Elder; Gerald G Krueger; Anne M Bowcock; Gonçalo R Abecasis
Journal:  Nat Genet       Date:  2009-01-25       Impact factor: 38.330

10.  Type I interferon: potential therapeutic target for psoriasis?

Authors:  Yihong Yao; Laura Richman; Chris Morehouse; Melissa de los Reyes; Brandon W Higgs; Anmarie Boutrin; Barbara White; Anthony Coyle; James Krueger; Peter A Kiener; Bahija Jallal
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

View more
  125 in total

1.  Phosphatidylglycerol Inhibits Toll-Like Receptor-Mediated Inflammation by Danger-Associated Molecular Patterns.

Authors:  Vivek Choudhary; Rawipan Uaratanawong; Ravi R Patel; Hirel Patel; Wendi Bao; Bernadette Hartney; Elyssa Cohen; Xunsheng Chen; Qing Zhong; Carlos M Isales; Wendy B Bollag
Journal:  J Invest Dermatol       Date:  2018-10-31       Impact factor: 8.551

2.  Effects of baicalin cream in two mouse models: 2,4-dinitrofluorobenzene-induced contact hypersensitivity and mouse tail test for psoriasis.

Authors:  Jie Wu; Hong Li; Ming Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 3.  Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.

Authors:  Smriti K Raychaudhuri; Ankit Saxena; Siba P Raychaudhuri
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

Review 4.  IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Authors:  Michele W L Teng; Edward P Bowman; Joshua J McElwee; Mark J Smyth; Jean-Laurent Casanova; Andrea M Cooper; Daniel J Cua
Journal:  Nat Med       Date:  2015-06-29       Impact factor: 53.440

Review 5.  The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis.

Authors:  Joshua A Zeichner; April Armstrong
Journal:  J Clin Aesthet Dermatol       Date:  2016-06-01

6.  Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature.

Authors:  Kunal Malik; Helen He; Thy Nhat Huynh; Gary Tran; Kelly Mueller; Kristina Doytcheva; Yael Renert-Yuval; Tali Czarnowicki; Shai Magidi; Margaret Chou; Yeriel D Estrada; Huei-Chi Wen; Xiangyu Peng; Hui Xu; Xiuzhong Zheng; James G Krueger; Amy S Paller; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2018-05-24       Impact factor: 10.793

7.  Anti-Psoriatic Drug Monomethylfumarate Increases Nuclear Factor Erythroid 2-Related Factor 2 Levels and Induces Aquaporin-3 mRNA and Protein Expression.

Authors:  Inas Helwa; Vivek Choudhary; Xunsheng Chen; Ismail Kaddour-Djebbar; Wendy B Bollag
Journal:  J Pharmacol Exp Ther       Date:  2017-05-17       Impact factor: 4.030

8.  Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy.

Authors:  Marco Galluzzo; Simone D'Adamio; Elena Campione; Luca Bianchi; Marina Talamonti
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

Review 9.  Immunology of psoriasis.

Authors:  Michelle A Lowes; Mayte Suárez-Fariñas; James G Krueger
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

Review 10.  Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.

Authors:  Jie Wang; Yow-Ming C Wang; Hae-Young Ahn
Journal:  AAPS J       Date:  2014-07-04       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.